Baxter International IncNYSE: BAX

No material news in the last 48 hours.

No material news in the last 48 hours.

No material news in the last 48 hours.

No material news in the last 48 hours.

Baxter International stock rose 3.0% to $18.33 on May 19, 2026, continuing recovery after dropping 3.2% to $17.31 on May 13 following a Bank of America Global Healthcare Conference presentation. On May 4, Baxter's board approved a new Executive Severance and Change in Control Plan replacing the prior severance program. Shareholders on May 5 approved all key governance and compensation items including director elections, an amended incentive plan, and a charter change on board size. Analyst sentiment is mixed: Goldman Sachs lowered its price target to $17 from $19 on May 1, while Barclays raised its target to $27 from $25 on May 3. The company announced a cash dividend with an ex-date of May 29. Average rating from 15 analysts is Hold with 12-month PT of $22.12.

Baxter Updates Executive Severance Plan and Governance Frameworktipranks.comBaxter International Inc. stock: Down 3.2% amid conference presentationad-hoc-news.deBaxter International Inc (BAX) Stock Up 3.0% and Still Undervaluedgurufocus.com

Baxter's board approved a new Executive Severance and Change in Control Plan on May 4 standardizing benefits for VPs and above, excluding CEO Andrew Hider. Shareholders on May 5 elected nine directors, ratified PwC as auditor, and approved a charter change setting board size at 7-12 directors. Goldman Sachs lowered its price target to $17 from $19 on May 1, while Barclays raised its target to $27 from $25 on May 4. The stock rose 2.05% on May 12, fell 3.2% on May 13 after a BofA Healthcare Conference presentation, then rose 3.0% on May 19. Q1 2026 revenue was $2.7B (up ~3% YoY) with international sales up ~12%. A $0.01 cash dividend has an ex-date of May 29.

Baxter Updates Executive Severance Governancetipranks.comBaxter Stock Up 3.0% Undervaluedgurufocus.comBaxter BofA Healthcare Conference 2026marketscreener.com

Baxter International reported Q1 2026 revenue of $2.70 billion (up 2.9% YoY) with international sales rising ~12% to $1.3 billion, and non-GAAP EPS of $0.36 beating consensus by 15.9%. Management reaffirmed full-year earnings guidance and analysts responded with more constructive commentary. On May 4, the board approved a new Executive Severance and Change in Control Plan that standardizes benefits for VPs and above; shareholders on May 5 approved all governance items including director elections, an amended incentive plan, and a charter change on board size. The stock rose 2.05% to $17.89 on May 12 but dropped 3.2% to $17.31 on May 13 following the Bank of America Global Healthcare Conference presentation. Consensus is Hold among 15 analysts with a $22.12 average target (~28% upside). Recent share price action follows a brutal one-year total return of -43.27%.

Baxter Updates Executive Severance Plan and Governance Frameworktipranks.comBAX Q1 Deep Dive: Turnaround Progress Amid Margin Pressures and Product Launchesfinancialcontent.comHow Investors May Respond To Baxter (BAX) Retiring Near-Term Debt And Advancing Connected Infusion Therapyfinance.yahoo.com

Baxter International stock declined 3.2% on May 13, 2026 to $17.31 following its presentation at the Bank of America Global Healthcare Conference 2026 on May 13, highlighting ongoing market scrutiny of its medical products positioning. The stock had rebounded 2.05% on May 12 to $17.89 amid support at recent healthcare sector lows. Analyst views are split: Barclays raised its price target to $27 from $25 on May 4, while Goldman Sachs lowered its target to $17 from $19 on May 1 and Stifel Nicolaus issued a Hold on May 3. Baxter adopted a new executive severance and change-in-control plan on May 4, expanding qualifying terminations and standardizing protections for senior leaders. Q1 2026 results posted earlier showed sales up 2.9% YoY to $2.70B, beating expectations.

Baxter International Inc. stock: Down 3.2% amid conference presentationad-hoc-news.deTranscript: Baxter International Inc. Presents at Bank of America Global Healthcare Conference 2026marketscreener.comBaxter Updates Executive Severance Plan and Governance Frameworktipranks.com

Baxter International shares dropped 3.2% to $17.31 on May 13, extending a 13% YTD decline versus the S&P 500's 5.6% gain. Goldman Sachs lowered its price target to $17 from $19 maintaining Neutral, while Barclays maintained Overweight with a $27 PT (~62% upside). At the May 5 annual meeting, shareholders elected nine directors, ratified PwC, and approved an amended incentive plan; the board also approved a new executive severance plan on May 4. Recent earnings showed a GAAP net loss but revenue beat. Baxter continues its three-pillar turnaround amid margin pressure and product launches.

Baxter International Inc (BAX) Stock Down 3.2%gurufocus.comBaxter Updates Executive Severance Plan and Governance Frameworktipranks.comBaxter International Stock Outlook: Wall Street Bullish or Bearish?finance.yahoo.com

Baxter International CEO Andrew Hider presented at the Bank of America Global Healthcare Conference on May 13, 2026. Shares rose 2.05% to $17.89 on May 12 after dropping 2.56% the prior day. Q1 2026 results topped revenue and non-GAAP profit expectations with reaffirmed full-year guidance for flat organic sales and improved 2H performance. On May 4 the board approved a new Executive Severance and Change in Control Plan and extended CEO Hider's health-benefit cash payment from 18 to 24 months in non-CIC termination. The May 5 annual meeting approved all five proposals including director elections. Barclays raised PT to $27 (from $25) while Goldman Sachs cut to $17 (from $19) keeping Neutral. Risk: 1-year total return is -43.27%, indicating prolonged weak momentum despite recent bounce.

Baxter Q1 2026 Resultsbusinesswire.comBaxter at BofA Healthcare Conferenceseekingalpha.comBaxter Updates Executive Severance Plantipranks.com

At the May 5 annual meeting, Baxter shareholders approved all five proposals including election of nine directors (each with 97%+ support), executive compensation, the amended incentive plan, and a board size charter change. The board adopted a new Executive Severance and Change in Control Plan on May 4, standardizing benefits for VPs and above (excluding CEO Andrew Hider). Q1 2026 results showed reported sales up 3% but organic sales down 1% and adjusted EPS down 35% YoY on tariff and cost headwinds. The company reaffirmed 2026 guidance for flat organic sales with improvement expected in H2. Shares are down roughly 46% over the past year. Risks include continued tariff pressure, weak organic growth, and the interim CFO situation.

Baxter International Shareholders Approve Board Slate, Pay and Incentive Plan at Annual Meetingdailypolitical.comBaxter Updates Executive Severance Plan and Governance Frameworktipranks.comBaxter profit plunges 35% as tariffs costs bitebenzinga.com

On May 4, 2026, Baxter's board approved a new Executive Severance and Change in Control Plan replacing the prior program for VPs and above, including Interim CFO Anita Zielinski (CEO Andrew Hider is excluded but had his offer-letter health-benefit cash payment extended to 24 months). The May 5 annual meeting elected nine directors, ratified PwC, approved the amended incentive plan, and set board size at 7-12. Barclays raised its price target to $27 from $25 on May 4 while Stifel kept a Hold. The board also declared a $0.01 cash dividend with a May 29 ex-date. Bear case: change-in-control plan adoption can be read as defensive positioning, and the stock is down ~45.9% over the past year as tariff costs continue to pressure margins.

Baxter Updates Executive Severance Plan and Governance Frameworktipranks.comWhat's Going On With Baxter International Stock Friday?benzinga.com

Baxter International adopted a new Executive Severance and Change in Control Plan effective May 4, 2026, replacing its prior plan and providing tiered cash, benefits and outplacement packages with higher multiples upon change in control. Shareholders preliminarily approved all five proposals at the May 5 annual meeting, including director elections, executive compensation, an amended incentive plan adding 20M shares, and a charter change on board size. The stock has declined 45.9% over the past year despite Q1 2026 revenue of $2.7B beating estimates. Analyst sentiment remains mixed with price targets around $23-27.

Baxter Updates Executive Severance Plan and Governance Frameworktipranks.comBaxter International Shareholders Approve Board Slate, Pay and Incentive Planfinance.yahoo.comBaxter expands severance protections and adds 20M incentive sharesstocktitan.net